LONDON – Ion Beam Applications SA (IBA) has taken a giant step into China, sealing a €100 million-plus (US$118.2 million) licensing deal with a local company to manufacture, install and maintain its proton beam cancer therapy systems.
LONDON – Engitix Ltd has secured Takeda Pharmaceutical Co. Ltd.’s endorsement of its extracellular matrix (ECM) technology in a potential $500 million deal in liver fibrosis.
While the COVID-19 pandemic has brought disruptions to R&D, market activities in the biopharmaceutical sector have remained active during the first half of this year in China. Venture capital investments, IPOs and partnering activity showed upward trends, except for M&A activity, which has declined for two years.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: 3Sbio, Can-Fite, Capricor, Cstone, FSD, Gilead Sciences, Hifibio, Laurent, Revive, Sirtex Medical US, Sound, TLC, Xortx.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Akari, Astrazeneca, Glaxosmithkline, Mereo, Orpheris, Ovid, Redhill, Takeda, Union, Vir.
The latest global regulatory news, changes and updates affecting biopharma, including: Department of Justice, Dusa, FDA, Michbio, Russian Ministry of Health, SEC, Stericycle Expert Solutions, Wintac.
RSS
